OncoMatch/Clinical Trials/NCT06239727
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Is NCT06239727 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for nasopharyngeal carcinoma.
Treatment: PD-1 blocking antibody · Gemcitabine · Cisplatin (80 mg/m2) · Cisplatin (100 mg/m2) · Capecitabine — This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication compared with conventional-dose radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage III NPC patients screened out according to the treatment response.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III
Excluded: Stage T3N0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: induction chemotherapy (GP regimen, Camrelizumab) — induction
Receive 3 cycles of indction chemotherapy (GP regimen + Camrelizumab)
Cannot have received: radiotherapy
Exception: non-melanoma skin cancer located outside the target volume of radiotherapy for nasophayngeal carcinoma
History of radiotherapy, except for non-melanoma skin cancer located outside the target volume of radiotherapy for nasophayngeal carcinoma
Cannot have received: other local or regional therapy
Receive treatment for the local or regional disease other than that specified in the research plan
Lab requirements
Blood counts
white blood cell count > 4×10^9/l, hemoglobin > 90g/l, platelet count > 100×10^9/l
Kidney function
creatinine clearance rate ≥ 60 ml/min
Liver function
total bilirubin ≤ 1.5 × uln, alanine transaminase and aspartate transaminase ≤ 2.5 × uln, alkaline phosphatase ≤ 2.5 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06239727 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages